Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.32 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4369936 | 0.87 | AOC3 (0.35) | AOC3TDP1LMNASLC6A2SLC6A4 | |
| SCHEMBL4381081 | 0.87 | TACR1 (0.38) | TACR1TDP1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL4373365 | 0.86 | AOC3 (0.39) | AOC3LMNASIGMAR1 | |
| SCHEMBL4370081 | 0.84 | TP53 (0.34) | AOC3LMNASIGMAR1 | |
| SCHEMBL15137381 | 0.83 | BRD4 (0.37) | AOC3LMNASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4370582 | 0.78 | TACR1 (0.37) | TACR1TDP1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL4379630 | 0.77 | EPHX1 (0.35) | AOC3LMNA | |
| SCHEMBL4371888 | 0.75 | TACR1 (0.35) | TACR1AOC3TDP1CACNA1FCACNA1D | |
| SCHEMBL4376387 | 0.73 | ALDH1A1 (0.39) | TDP1LMNASLC6A2SLC6A4 | |
| SCHEMBL4374651 | 0.72 | NOS2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1867654-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | NAGOYA IND SCIENCE RES INST (JP) | 2014-06-11 | — | — | EP | disclosed |
| EP-2623509-A1 | Method of producing an optically active amine compound by catalytic asymmetric hydrogenation using a ruthenium-diphosphine complex | Kanto Kagaku Kabushiki Kaisha (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2013-08-01 | — | — | US | disclosed |
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA | 2009-08-27 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
| EP-1323724-B1 | Ruthenium complexes and process for preparing alcoholic compounds using these | KANTO KAGAKU (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-6790973-B2 | REDUCTION OF KETONE TO ALCOHOL USING COMPLEX CATALYST | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030166978-A1 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1323724-A2 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | Kanto Kagaku Kabushiki Kaisha (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | NQO2, ADH7, MRPL21 | TACR1 3091/4885AOC3 951/4885TDP1 1933/4885 |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | HRH3, TDO2, SRM | TACR1 2591/4885AOC3 523/4885TDP1 3532/4885 |
| US-20030166978-A1 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | ADH1C, ADH1A, ADH5 | TACR1 2534/4885AOC3 1442/4885TDP1 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.